Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective

enthalten in: PharmacoEconomics | 2022

von Pratz, K. | Chai, X. | Xie, J. | +6

Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices

enthalten in: Leukemia & lymphoma | 2017

von Skarbnik, A. | Ma, E. | Lafeuille, M. | +7

Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014)

enthalten in: Journal of clinical oncology / Englische Ausgabe | 2016

von Gnanasakthy, A. | DeMuro, C. | Clark, M. | +3